EIF3A and hepatocellular carcinoma: Therefore, it was concluded that eIF3a might be a potential therapeutic target for hepatic carcinoma (HCC) since it acts as a regulator for glycolysis—a process that is central to cancerous reprogramming of metabolism [34].